NCT05433480 2023-07-27
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
Clinical Trials
6 trialsNCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02383030 2016-06-15
FUMANCE
Consorzio Oncotech
Phase 3 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown